The Australasian unveiling of ZEISS’ CIRRUS PathFinder – described as a breakthrough in AI-guided OCT image assessment – took place at ODMAFair25 in Sydney recently.
A fully integrated, AI-based support tool, CIRRUS PathFinder aims to enhance clinical decision-making by assisting with OCT interpretation. Designed to complement clinical workflows, ZEISS said the technology can streamline the review of macular OCT scans by automatically identifying scans potentially requiring closer examination.
CIRRUS PathFinder is now available on ZEISS CIRRUS 500, 5000, and 6000 devices.
ODMAFair, featuring leading clinical optometry professionals from across the country between 27-29 June 2025, made for an ideal setting to launch the technology, ZEISS said.
“CIRRUS PathFinder employs state-of-the-art deep learning algorithms, trained on over 75,000 OCT B-scan images, to automatically flag abnormalities in macular scans,” ZEISS said in a statement.
“From subretinal fluid (SRF) to retinal pigment epithelium (RPE) atrophy, PathFinder helps pinpoint subtle changes that could indicate early signs of disease.”
Why use CIRRUS PathFinder
- Supporting smarter diagnoses, faster: By flagging scans of interest, ZEISS stated PathFinder can support clinicians in detecting retinal abnormalities.
- Streamlined workflows: Integrated directly into the CIRRUS platform,* PathFinder eliminates the need for third-party tools.
- Confidence eyecare professionals can trust: Validated through peer-reviewed research and developed in collaboration with leading retinal specialists, PathFinder has been shown to deliver 88% sensitivity and 93% specificity.*
More reading
ZEISS secures Brighten Optix contact lens acquisition
Eyes the winning focus in ZEISS photo gallery exhibition
$100,000 worth of ZEISS technology up for grabs in competition
References:
*Talcott E, Valentim C, Perkins S, Ren H, Manivannan N, Zhang Q, Bagherinia H, Lee G, Yu S, D’Souza N, Jarugula H, Patel K, Singh R. Automated Detection of Abnormal Optical Coherence Tomography B-scans Using a Deep Learning Artificial Intelligence Neural Network Platform. Int Ophthalmol Clin. 2024 Jan;64(1):115-127.
